{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:39:14Z","timestamp":1792841954359,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.brachy.2026.07.168","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:15:53Z","timestamp":1790421353000},"page":"953-962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["High-dose-rate brachytherapy boost with external beam radiotherapy for localized prostate cancer: Long-term outcomes and toxicity in 607 predominantly high-risk patients"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-7990","authenticated-orcid":false,"given":"Mahbuba","family":"Choudhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9885-3960","authenticated-orcid":false,"given":"Femi","family":"Adeoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiji","family":"Nageshwaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-5936","authenticated-orcid":false,"given":"Fanny Joceyln","family":"Amalraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasinul","family":"Wasee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khin","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dakshinamoorthy","family":"Muthukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie Eyre","family":"Mchugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0943-4882","authenticated-orcid":false,"given":"Daben","family":"Dawam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8323-9567","authenticated-orcid":false,"given":"Peter","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imtiaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2026.07.168_bib0001","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2026.07.168_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external beam radiotherapy alone or with high-dose rate brachytherapy for prostate cancer: mature 12year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2026.07.168_bib0003","doi-asserted-by":"crossref","DOI":"10.1097\/COC.0b013e3181b9cd2f","article-title":"High-dose rate prostate brachytherapy: an excellent accelerated hypofractionated treatment for favourable prostate cancer","volume":"33","author":"Martinez","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.brachy.2026.07.168_bib0004","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.06.154","article-title":"Randomized trial comparing iridium implant plus external beam radiation therapy with external beam radiation therapy alone in node negative locally advanced cancer of the prostate","volume":"23","author":"Sathya","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2026.07.168_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109632","article-title":"Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk prostate cancer patients","volume":"183","author":"Miszczyk","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2026.07.168_bib0006","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1111\/bju.13659","article-title":"Longterm outcomes of high-dose rate brachytherapy for intermediate and high risk prostate cancer with a median follow-up of 10 years","volume":"120","author":"Yaxley","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2026.07.168_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.109460","article-title":"Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: a retrospective bicenter study by the SFRO brachytherapy group","volume":"180","author":"Ka","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2026.07.168_bib0008","doi-asserted-by":"crossref","first-page":"9099","DOI":"10.1016\/j.ijrobp.2023.11.011","article-title":"Timing of high-dose rate brachytherapy with external beam radiation therapy in patients with intermediate and high-risk localised prostate cancer and its effects on toxicity and quality of life: a randomised controlled trial (THEPCA)","volume":"119","author":"Choudhury","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2026.07.168_bib0009","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clon.2017.02.015","article-title":"High dose rate brachytherapy as monotherapy for localised prostate cancer: review of the current status","volume":"29","author":"Tselis","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.brachy.2026.07.168_bib0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijrobp.2025.03.053","article-title":"A randomized comparison of high-dose-rate and low-dose-rate prostate brachytherapy combined with external beam radiation therapy for unfavorable prostate cancer: efficacy results after median follow-up of 74 months","volume":"123","author":"Crook","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2026.07.168_bib0011","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.brachy.2025.06.005","article-title":"High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: an evidence-based consensus statement","volume":"24","author":"Patel","year":"2025","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2026.07.168_bib0012","series-title":"East of England region: clinical guidelines for the management of prostate cancer","year":"2025"},{"key":"10.1016\/j.brachy.2026.07.168_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2021.12.047","article-title":"GECESTRO ACROP prostate brachytherapy guidelines","volume":"167","author":"Henry","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2026.07.168_bib0014","article-title":"Focal boost to the intraprostatic tumour in external beam radiotherapy for patients with localised prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Monninkhof","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2026.07.168_bib0015","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumour for intermediate- and high-risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"186","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2026.07.168_bib0016","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20130617","article-title":"Simultaneous integrated boost to intraprostatic lesions using volumetric modulated arc therapy in prostate cancer: feasibility and early toxicity","volume":"87","author":"Onal","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.brachy.2026.07.168_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk nonmetastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.brachy.2026.07.168_bib0018","first-page":"789","article-title":"Two-year toxicity outcomes from PACE-C: stereotactic body radiotherapy (SBRT) versus moderate hypofractionated radiotherapy (MHRT)","volume":"118","author":"Ratnakumaran","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472126002758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472126002758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:33:33Z","timestamp":1792841613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472126002758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1538472126002758"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2026.07.168","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose-rate brachytherapy boost with external beam radiotherapy for localized prostate cancer: Long-term outcomes and toxicity in 607 predominantly high-risk patients","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2026.07.168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc. on behalf of American Brachytherapy Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}